[教育]早期乳腺癌辅助化疗进展.pptVIP

[教育]早期乳腺癌辅助化疗进展

BreastCancerIncidenceTrendsOverTime

CancerIncidenceTrendsinChina2005–2015

IncidenceRatesProjectionbyCancerType

Per100,000

CAGR2.98%

CAGR4.5%

CAGR0.65%

CAGR–2.35%

CAGR0.99%

CAGR2.60%

Source:EstimatesofCancerIncidenceinChinafor2000andProjectionsfor2005,YangL,etal.

中国乳腺癌发病概况

每年约有19万新发乳腺癌病例

2002年全国乳腺癌年龄标化发病率:18.7/100,000；死亡率:5.5/100,000

发病率:城市＞农村

高发年龄段:45－50岁

近15年来乳腺癌

发病率上升

死亡率下降

死亡率下降的原因

早期诊断

综合治疗

Thebenefitsofchemotherapy

datafromclinicaltrails

EarlyBreastCancerTrialistsCollaborativeGroup(EBCTCG).

194randomisedtrialsofadjuvantchemotherapy(CMF,CAF,CEF)orhormonaltherapy(TAM)thatbeganby1995.

Lancet2005

Placebo

53.3%

37.1

47.9

Time(years)

0

5

15

10

Recurrence

(%)

15-yeargain12.3%(SE1.6)

Log-rank2p0.00001

15-yearprobabilitiesofrecurrenceinwomenaged50years,with/withoutpolychemotherapy

Polychemotherapy

41.1%

35.5

24.6

Youngerwomen,35%node-positive;

olderwomen,70%node-positive;

SE=standarderror

EBCTCG.Lancet2005;365:1687-1717

Placebo

42.4%

20.4

35.0

Breast

cancer

mortality

(%)

15-yeargain10.0%(SE1.6)

Log-rank2p0.00001

Polychemotherapy

32.4%

Time(years)

0

5

15

10

15.7

27.1

15-yearprobabilitiesofbreastcancermortalityinwomenaged50years,

with/withoutpolychemotherapy

EBCTCG.Lancet2005;365:1687-1717

Youngerwomen,35%node-positive;

olderwomen,70%node-positive

15-yeargain4.1%(SE1.2)

Log-rank2p0.00001

Placebo

57.6%

Polychemotherapy

53.4%

48.8

0

5

15

10

35.4

44.1

29.4

15-yearprobabilitiesofrecurrenceinwomenaged50-69years,with/withoutpolychemotherapy

Time(years)

EBCTCG.Lancet2005;365:1687-1717

Recurrence

(%)

Youngerwomen,35%node-positive;

olderwomen,70%node-positive

Placebo

50.4%

21.3

38.3

15-yeargain3.0%(SE1.3)

Log-rank2p0.00001

Polychemotherapy

47.4%

18.7

0

5

15

10

35.4

15-yearprobabilitiesofbreastcancermortalityinwomenaged50-69years,

with/withoutpolychemotherapy

Time(years)

Youngerwo